{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-056424","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.184318+00:00","generated_at":"2026-06-02T23:51:39.242226+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital","bullets":["Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.","14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).","10% original issue discount; prepayment allowed with 10% charge.","Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-056424","json":"https://secwatch.observer/filing/0001104659-24-056424.json","markdown":"https://secwatch.observer/filing/0001104659-24-056424.md","text":"https://secwatch.observer/filing/0001104659-24-056424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/tm2413348d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:51:39.242226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b56b9ad0f1a40377470ee03b02d1308c6efb59a","claim":"NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.","evidence_excerpt":"On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$11,005,000"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"22 months"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"4ba5788f82f02c47bde1d93f97a4abe36bd04e18","claim":"NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2024-04-26).","evidence_excerpt":"On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$11,005,000"},{"label":"Effective","value":"2024-04-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}